Background
==========

Insulin-like-growth factor II (IGF II)^b^\[somatomedin A \] is a mitogenic polypeptide having structural similarity to proinsulin and insulin-like-growth factor I (IGF I) \[somatomedin C\] \[[@B1],[@B2]\]. IGF II is known to be widely distributed in various fetal and neonatal human and rat tissues, including liver \[[@B3]-[@B5]\], but restricted in the adult rat tissues \[[@B6]\], except brain \[[@B7]\]. It has also been implicated in the pathogenesis of neoplasm of different tissues, including liver of rats and men \[[@B8]-[@B11]\]. The growth factor is believed to exert their effect during cellular proliferation through endocrine, autocrine and paracrine mechanisms \[[@B12]\]. In breast cancer epithelial cells, IGFII was reported to serve as autocrine growth stimulus and IGFII overexpression was suggested to be capable of mediating malignant progression \[[@B13]\]. Expression of IGFII in rodents remains high around birth and becomes undetectable within three weeks \[[@B14]\]. But the reactivation of this gene has been reported in variety of neoplasms including HCC in rats. IGF II expression has been shown to be reactivated during progression of neoplastic nodules to HCC \[[@B15]\]. IGFII reactivation was reported to be a common phenomenon in hepatocarcinogenesis irrespective of species and the process of hepatocarcinogenesis \[[@B11]\]. The reactivation of endogenous IGF II was suggested to exert a growth stimulatory effect via IGFI and IGFII/mannose 6 phosphate receptors \[[@B16]\]. It was stated that IGFII might trigger a proliferating signal through hybrid insulin/IGFI receptors stimulated by exogenous IGF \[[@B17]\]. Carcinogen treatment may generate IGFII microenvironment in preneoplastic foci that lead to selective growth advantage for this cell.

Chemical hepatocarcinogenesis is a multistep and complex process and is a favorite model in rat to study the mechanism of transformation of a normal cell to malignant population(s) \[[@B18]\]. During the process of development of HCC from the normal hapatocytes, hepatic altered foci appear. These foci are the putative precursors of HCC in rat, and probably in man \[[@B19],[@B20]\]. Depending on the morphological and biochemical hepatocellular changes during the process of development from normal hepatocytes to HCC induced by various chemical carcinogens, radiation, hormones, chronic viral hepatitis and transgenic manipulation in rodents, three main altered hepatocellular lesions-the glycogenotic, mixed cell and basophilic cell lesions have been distinguished \[[@B21]\]. The predominant sequence of cellular changes starts with glycogenotic clear and acidophilic (smooth endoplasmic reticulum- rich) hepatocytes and progresses through intermediate phenotypes in mixed cell populations to glycogen-poor, homogeneously basophilic (ribosome -rich) cellular phenotypes prevailing in undifferentiated HCC.

Elevated levels of IGF II gene and protein expression have been found in a wide range of human and rodent tumors \[[@B8]-[@B10]\]. IGF II has been claimed to be one of the most important growth factors, playing role during the progression of neoplasm \[[@B22]\]. But the advent of IGF II gene expression during the development of neoplasia has remained to be elucidated. Antisense *in situ*hybridization technique has been used here to explore the type(s) of foci in which IGF II mRNA is expressed at the stages of neoplastic conversion of hepatocytes during diethylnitorsamine (DENA)-induced and phenobarbital promoted hepatocarcinogensis in Sprague-Dawley rats.

Materials and methods
=====================

Experiments were conducted on the hepatic tissues of male Sprague-Dawley rats (purchased from the Indian Institute of Chemical Biology, Kolkata, India). The initial body weights of the animals were approximately 130 g. They were maintained under constant temperature (22°C) and humidity (55%RH) conditions and were fed basal diet \[[@B23]\] and had free access to water. Animals were divided in four groups-Group A (having 15 animals), group B, C and D (having 10 animals in each of the three groups). Group A animals were normal untreated animals. Group B, C and D animals were carcinogen treated groups. All carcinogen treated animals were treated with DENA, 200 mg/kg body weight, intraperitoneally at the start of the experiment, i.e., day zero. Group C and D animals were promoted with 0.05 % phenobarbital in basal diet \[[@B24]\]. Group B animals were sacrificed at the 8^th^week to study earlier preneoplastic lesions, group B animals were sacrificed at 22^nd^weeks to study mixed and basophilic lesions and group C animals were sacrificed at 36^th^week as HCC development are reported to take place between 32--36 weeks \[[@B25]\]. In each case five normal control animals were sacrificed with the respective treated groups B, C and D for comparison. All animals were unfed for 12 h before they were sacrificed by cervical dislocation and the animals were sacrificed between 9 and 10 a.m. The livers were removed, sliced (5--10 mm thick) and were snap-frozen in isopentane precooled with liquid nitrogen at -- 150°C. The tissues were stored at -- 80°C until further used.

Serial sections were prepared from the frozen materials with a Reichert-Jung microtome. They were studied histochemically by periodic acid Schiff reaction, toluidine blue and hematoxylin-eosin to detect different hepatic altered foci (26, 27). Preneoplastic lesions were eventually divided into three categories in accordance with their respective size and the total area of the occupied liver parenchyma (\<1 mm, \>1 mm-\<3 mm, \>3 mm) as described previously \[[@B28]\]. These serial sections were used for *in situ*hybridization with sense and anitsense digoxigenin labeled mRNA probes of IGF II and immunohistochemical reaction for *proliferating cell nuclear antigen*(PCNA).

In vitro transcription of Digoxigenin (DIG)-labeled sense and antisense IGF II mRNA
-----------------------------------------------------------------------------------

A 860 base pair (bp) coding region fragment from rIGF II cDNA extended between EcoRI- EcoRI ploylinker site of pGEM-4 vector (Source: H. Hacker, DKFZ, Germany, obtained from A Riccio, Universita degli studi di Napoli Federico II, Napoli, Italy) was transformed into XL1-blue *E.coli*competent cells. The plasmid was also religated and propagated in the competent cells to obtain the opposite orientation of the 860 bp coding fragment of rIGF II cDNA. SP6-RNA polymerase was used to generate both sense and anitsense riboprobes from Xba I linearized plasmids of the opposite orientation. *In vitro*transcription was conducted, using digoxigenin (DIG)-RNA labeling Kit from Boehringer-Mannheim, Mannheim, Germany. The concentrations of the sense and antisense probes were estimated by using Nucleic Acid Detection Kit (Boehringer- Mannheim, Mannheim, Germany). The method is based upon the comparison between the colour intensities of slot blots and DIG labeled standard (Boehringer- Mannheim, Mannheim, Germany) (Figure [1](#F1){ref-type="fig"}) and the experimental riboprobes. By electrophoresing the probes on formaldehyde containing 1% agarose gel the purity of the labeled probes were checked (Figure [2](#F2){ref-type="fig"}).

![Quantification of DIG-labeled sense and antisense IGFII mRNA by spot test against standard labeled mRNA (Boehringer-Mannheim RNA detection kit).](1477-3163-4-12-1){#F1}

![Detection of DIG-labeled IGFII sense and antisense mRNA (860 bp) using gel electrophoresis. Lane 1; DIG-labeled sense IGFII mRNA, Lane 2; DIG-labeled antisense IGFII mRNA.](1477-3163-4-12-2){#F2}

Detection of IGF II mRNA by *In situ*hybridization
--------------------------------------------------

*In situ*hybridization was conducted on 6 μm cryosections of the liver samples by using a modified procedure of Braissant and Walhi \[[@B29]\]. The cryosections were first fixed at 50°C for 30 seconds on a hot plate and delipidified with chloroform for 5 min whenever necessary. The sections were then fixed in 4% paraformaldehyde in phosphate buffer saline, pH 7.4, (PBS) for 1 hr. The slides were then treated with PBS containing active DEPC (diethyl pyrocarbonate) for 30 min followed by a wash of 4 × SSC of 15 min. Prehybridization was conducted using hybridization buffer (mentioned below) except dextran sulphate and Denhardt\'s solution for 1 hr. at 52°C. This was followed by hybridization at 50°C overnight in a humid chamber. Every 10 ml of hybridization buffer contained 5 ml deionized formamide, 2.4 ml DEPC treated water, 2 ml 20 × SSC, pH 7.0, 1 g dextran sulphate, 200 μl 50 × Denhardt\'s solution, denatured yeast t-RNA (10 mg/ml) 400 μl and denatured salmon sperm DNA (10 mg/ml) μl along with respective probes denatured by heating at 80°C for 3 min., followed by immediate cooling on ice. After hybridization, sections were washed in 2 × SSC at room temperature (RT) for 30 min, then again with 2 × SSC at 60°C, for 30 min. This was followed by 1 × SSC for 30 min and 0.1 × SSC for 1 hr, at 60°C with a frequent moderate shaking. After the stringency wash, the slides were incubated with Tris-NaCl buffer, pH 7.5 containing 0.5% blocking agent (Boehringer-Mannheim, Mannheim, Germany) at RT on a shaking platform with a low speed. Sections were then incubated with anti-DIG-polyclonal antibody conjugated with alkaline phosphatase (Boehringer-Mannheim, Mannheim, Germany) (1:5000) in Tris-NaC1 buffer, pH 7.5 for 2 hr at RT on the shaking platform with a low speed. After incubation, sections were washed with washing buffer (Tris-NaC1 buffer, pH 7.5, containing 0.3% tween 20) for 10 min at RT. This was followed by two 15 min washes with Tris-NaC1 buffer, pH 7.5. the section were equilibrated with detection buffer (100 mM Tris-HC1, 100 mM NaC1 and 50 mM MgC1~2~,6H~2~O), pH 9.5 for 5 min and staining was done using nitroblue tetrazolium/ bromochloroindolylphosphate (NBT/BCIP) in detection buffer. Counter staining was also done occasionally.

Immunohistochemical detection for *proliferating cell nuclear antigen*
----------------------------------------------------------------------

PCNA was demonstrated by following the methods of Enzmann et al. \[[@B30]\] and Bannasch et al \[[@B31]\]. Briefly 6 μm cryostat sections were air-dried after fixation in acetone for 10 min followed by a treatment with 2% H~2~O~2~in methanol to block endogenous peroxidases. Then the sample was incubated in 3% bovine serum albumin for 30 min to prevent unspecific reactions followed by incubation with mouse monoclonal antibody to PCNA, diluted 1:1600 (PC10 Dako), overnight at 4°C. PCNA positive nuclei were identified by using alkaline phosphatase labeled streptavidine-biotin complex (Dako LASB2 Kit, AP). Then the sections were stained with new-fuschin and Myer\'s haemetoxylin.

IGF II mRNA positive foci were estimated in randomly selected areas of each section containing hepatic altered foci from experimental animals. The results were statistically evaluated using ANOVA followed by Fisher\'s exact Test otherwise mentioned.

Results
=======

The morphometric determination of the focal lesions showed that incidences of preneoplastic lesions (i.e. glycogen storage foci/acidophilic foci \[Figure [3](#F3){ref-type="fig"}\], mixed cell focal lesions and basophilic focal lesions \[Figure [4](#F4){ref-type="fig"}\] were 100% in group B, C and D animals. The numerical densities and size distributions of preneoplastic lesions were depicted in Table [1](#T1){ref-type="table"}. Average numerical density was found to be maximum (1498 ± 33 per cm^3^of hepatic tissue) in case of group D animals, which was followed by group C (968 ± 16 per cm^3^of hepatic tissue) and group B (412 ± 28 per cm^3^of hepatic tissue) animals. The preneoplastic lesions were categorized with respect to their sizes and their areas of the occupied liver parenchyma. It was observed that group B animals in which carcinogenesis had been initiated with DENA and animals were sacrificed after 8 weeks, had 81% focal lesions having size less than 1 mm i.e. smaller lesions and 19% focal lesions were in the size range of 1 mm-3 mm. Group C had 52% lesions less than 1 mm. 44% lesions were between 1 mm and 3 mm and sizes of 4% lesions were greater than 3 mm. In group D animals, seven animals out of ten were found to develop HCC (Table [2](#T2){ref-type="table"}) and they had more intermediate (1 mm-3 mm) and large (greater than 3 mm) lesions as compared to smaller lesions.

###### 

Incidences, numbers and size distributions of preneoplastic lesions (glycogen-storage, mixed cell and basophilic type) in the hepatic tissues of male Sprague-Dawley rats in different experimental groups (B, C and D).

  Group   No. of rats with preneoplastic lesions/Total numbers of rats   Incidences (%)   Numerical densities of preneoplastic lesions^a,b^   Size distributions of preneoplastic lesions (% of total numbers)        
  ------- -------------------------------------------------------------- ---------------- --------------------------------------------------- ------------------------------------------------------------------ ---- ----
  B       10/10                                                          100              412 ± 28                                            81                                                                 19   \-
  C       10/10                                                          100              968 ± 16                                            52                                                                 44   4
  D       10/10                                                          100              1498 ± 33                                           20                                                                 48   32

^a^Numerical density, expressed in number per cm^3^of hepatic tissue

^b^Each value represent mean of 10 rats per group ± SD

###### 

Expression of IGF II gene in different types of preneoplastic hepatic altered focal lesions (HAF) as well as carcinoma in hepatic tissues of the experimental animals (group B, C and D)

  Types of HAF which expressed IGF II gene   Numbers of rats with HAF and/or HCC per total no of animals   Number of IGF II expressed lesions/100 respective HAF lesions
  ------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------------
  Glycogen-storage focal lesion              10/10                                                         98 ± 2.98^a,^\*
  Mixed cell focal lesion                    10/10                                                         74 ± 8.26^a,^\*
  Basophilic cell focal lesion               10/10                                                         05 ± 2.68^a,NS^
  Hepatocellular carcinoma                   7/10                                                          95 ± 4.02%^b,^\*

^a^Mean ± SD (n = 10)

^b^Mean ± SD (n = 7)

\* P \< 0.001

NS- Non-significant

![Glycogen storage foci (shown by yellow arrows) in rat hepatic tissue with Periodic Acid Schiff reaction, ×100.](1477-3163-4-12-3){#F3}

![Mixed cell focal lesion (shown by green arrows) and basophilic lesion (shown by blue arrows) in DENA treated rat liver, ×100.](1477-3163-4-12-4){#F4}

When IGFII gene expressed, preneoplastic lesions were compared to the various type of hepatic altered foci (HAF) such as glycogen storage focal lesions, mixed cell focal lesions, and basophilic focal lesions, it was found that 98% glycogen storage focal lesions expressed IGFII \[Figures [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}\]. Again 74% of the mixed cell focal lesions expressed IGFII where once again mainly glycogen storage hepatocytes were found to express IGFII not the basophilic cells. Very few basophilic cell focal lesions with IGFII gene expression were detected. In those lesions, there were, some glycogen containing cells (as seen with PAS staining). As the lesions containing predominantly basophilic cells, they were categorized under basophilic lesions. Thus it may be believed that glycogen storage cells showed IGFII expression in those basophilic lesions. Only 5% of the basophilic hepatic altered foci were found to express IGFII although the results are statistically non-significant. As described earlier in group D animals, seven out of ten animals were found to develop HCC and they had some high expression in the peripheral hepatocytes of tumor. There was also some expression within the tumor areas \[Figures [8](#F8){ref-type="fig"}, [9](#F9){ref-type="fig"}, [10](#F10){ref-type="fig"}, [11](#F11){ref-type="fig"}\].

![Hepatic section of DENA treated experimental animals showing glycogen storage foci with PAS staining, ×100.](1477-3163-4-12-5){#F5}

![IGFII mRNA expressed glycogen storage lesion detected with Digoxigenin-labeled antisense IGFII, mRNA ×100.](1477-3163-4-12-6){#F6}

![Glycogen storage lesion shown after Digoxigenin-labeled sense IGFII mRNA treatment during in situ hybridization method ×100. Pv- portal vein. Bd -- bile duct.](1477-3163-4-12-7){#F7}

![Section of hepatic tumor (shown by arrows) in HCC; using toluedine blue ×40.](1477-3163-4-12-8){#F8}

![Section of hepatic tumor (shown by arrows) in HCC; using PAS reaction ×40.](1477-3163-4-12-9){#F9}

![Section of hepatic tumor (shown by arrows) in HCC; IGFII mRNA expression detected with DIG-labeled IGFII antisense mRNA in tumor as well as peripheral tissue. ×40.](1477-3163-4-12-10){#F10}

![IGFII mRNA expression in hepatocytes in tumor area during HCC in experimental animals (see protocols) ×97.5.](1477-3163-4-12-11){#F11}

Hepatocytes proliferation was established by demonstration of PCNA (Proliferating Cell Nuclear Antigen). PCNA positive hepatocytes and non-hepatocytes were detected in carcinogen treated groups as well as normal untreated groups. Five fold higher numerical value of PCNA positive cells was detected in the carcinogen treated animals as compared to normal untreated animals (Table [3](#T3){ref-type="table"}) and PCNA positive cells in carcinogen treated animals were mostly (about 85%) confined to lesion area. Interestingly the counts were greater in glycogen storage lesions as well as in HCC (data not shown). This indicates that proliferation was higher during the early stage i.e. at the immediate post initiation stage as well as in HCC.

###### 

Number of PCNA (Proliferating Cell Nuclear Antigen) positive liver cells per 10^3^cells

  [Labeling Index^a^]{.ul}                
  -------------------------- ------------ ------------
  Carcinogen-treated         667 ± 28\*   122 ± 17\*
  Normal Control             132 ± 12     88 ± 14

^a^results show mean ± SD (n = 10)

\* P \< 0.001 as compared to normal control animals, assessed by Student\'s *t*-test

In the hepatic tissue of group D animals some scattered spongiotic pericytoma have been noticed. This spongiotic pericytoma are also believed to be the precursor of perisinusoidal cell sarcomas \[[@B32]\]. They were very few in numbers but were found in the hepatic tissue of all the animals in group D. But they were not found in every tissue slide of the same animals. When IGFII expression of the subsequent slides were studied it was observed that IGFII gene did not express in the area of spongiotic hepatis. But high IGFII expression was noticed at the peripheral hepatocytes \[Figures [12](#F12){ref-type="fig"}, [13](#F13){ref-type="fig"}, [14](#F14){ref-type="fig"}, [15](#F15){ref-type="fig"}\]. PCNA positive cells were also detected predominantly in the peripheral cells of spongiosis hepatis.

![Serial sections of experimental rat hepatic tissue showing spongiosis hepatis with haematoxylin and eosin (shown by white arrows) ×40.](1477-3163-4-12-12){#F12}

![Section of experimental rat hepatic tissue showing spongiosis hepatis with toluedine blue ×120.](1477-3163-4-12-13){#F13}

![Section of experimental rat hepatic tissue showing spongiosis hepatis with PAS reaction) ×40.](1477-3163-4-12-14){#F14}

![IGFII mRNA expression detected by DIG- labeled antisense IGFII mRNA in the peripheral cells of the spongiocyst hepatis ×120.](1477-3163-4-12-15){#F15}

Discussion
==========

A predominant sequence of cellular changes starting from the appearance of glycogenotic foci to the glycogen-poor basophilic foci, leading to HCC via various mixed cell populations, has been observed in rodents during the development of HCC induced by various chemical carcinogens, hormones, radiation, chronic viral infection and transgenic manipulation \[[@B19],[@B20]\]. During this process several phenotypic changes appear which suggest a progressive cellular dedifferentiation.

The DIG detection system used here has been claimed to offer a much higher sensitivity and detectability than radioactive detection systems \[[@B33],[@B34]\]. Using this system, we tried to localize the IGF II gene expression in different type(s) of foci during DENA-induced hepatocarcinogenesis. Predominant expression of the gene was located in hepatic altered glycogen-storage foci which has been claimed to be early preneoplastic lesions \[[@B32]\] along with some expressions in foci of mixed cell populations. High expression was also detected in HCC. It was higher at the periphery as well as the glycogen storage cells of the tumor. This observation is supported by the observation of Sohda *et.al*who demonstrated that the localization of IGF II mRNA in areas consisting of less differentiated tumor were present at the periphery of the tumour nest \[[@B35]\]. Higher expression was detected in the foci of glycogen storage altered hepatocytes as compared to the tumor cells. This suggests that there is a differential expression of IGF II mRNA during the development of preneoplasia to neoplasia. Fetal transcripts of IGF II express high in man and rodent liver cancer \[[@B6]\]. In human, fetal transcripts express highly in the HCC, suggesting that IGF II-expression is late event during the development of liver cancer \[[@B36]\]. On the other hand, an inverse correlation was observed between IGF II-expression and cellular differentiation in rat \[[@B37]\]. Again, it has been found that the IGF II expression is predominant at the fetal and neonatal life of rat and it declines with the days after birth when IGF I is found to be increased and believed to take up the role of IGF II \[[@B6]\]. Simultaneously increased pattern of expressions of IGF I and TGFα, during some preneoplastic and neoplastic conditions \[[@B35]\] also suggests that the IGF I and TGFα may counterbalance the activity of IGF II.

Amongst the various methods available, two important methods of studying cancer cell proliferation are measuring the rate of DNA synthesis and the immunohistochemical reaction for *proliferating cell nuclear antigen*(PCNA) \[[@B30],[@B31]\]. Demonstration of PCNA has been reported to be a valuable non-tracer method for the detection of proliferating cells. Report suggests the method is used to detect proliferating cells in S phase, G2 and late G1 phases of the cell cycles \[[@B32]\]. PCNA positive liver cell counts were found to be significantly higher (p \< 0.001) in this study in carcinogen treated animals as compared to normal control animals. Higher PCNA labeling index were noticed in IGF II expressed lesions (mostly glycogen-rich lesions) as compared to the other IGF II non-expressed or little-expressed hepatic lesions (mixed cells and basophilic cell lesions) in hepatic areas studied. This suggests that the IGF II expressed cells in all the lesions are more proliferating in nature as compared to the other focal lesions and of course the extra-focal hepatic areas. The labeling index was found to be higher again in HCC. This indicates that cancer development is faster during glycogen-rich focal development (they predominantly expressed IGF II) and during the stage of HCC.

Spongiosis hepatis have been found interestingly only in-group C animals (in six out of ten animals). They were found to be very scattered in nature. In whole observation they were only 18 in numbers (in 50 different hepatic tissue samples of the seven animals of group C). Thus it seems that they appear in progression phase of cancerous process, at least during DENA-induced hepatocarcinogenesis. Spongiosis hepatis also described as spongiotic pericytoma are believed to be the possible precursor of malignant tumors \[[@B32]\]. It has also been classified as perisinusoidal (ito) cell sarcomas \[[@B33]\]. Lesions classified as spongiosis hepatis have been reported to progress to pericytomas which have been related to perisinusoidal cells (ito cells). Thus the study of these cells may help to understand neoplastic transformation of them. In present study efforts have been made to characterize various preneoplastic hepatic altered foci and hepatic cellular carcinoma along with spongiosis hepatis. Spongiosis hepatis have been detected using haematoxylin and eosin, toluidine blue and PAS staining. Consecutive sections were compared with the IGFII expressions and it has been observed that the predominant expression of IGFII were noticed in the peripheral hepatocytes but not in the holes of the spongiotic formations which are believed to be filled with a finely flocculent material that shows metachromasia (Acid mucopolysaccharide deposit) \[[@B32]\]. The IGFII expression seems to be dominant more in the peripheral hepatocytes of the spongiocyst hepatis. PCNA positive cells were also detected in the surrounding areas where the IGFII expressions were noticed. Again IGFII expression has been claimed to be associated with the development of hepatocellular carcinoma (HCC) by several authors \[[@B34],[@B35]\]. Thus the study further supports that the spongiosis hepatis are possibly the origin of malignant tumor \[[@B32]\]

The claims related to an amount of over expression of IGF II gene in liver tumors and pre-neoplastic hepatic lesions during hepatocarcinogenesis in animal models and in human HCC were highly variable. A possible involvement of an IGF II autocrine loop in the pathogenesis of hepatic preneoplastic and neoplastic lesions have been linked with the association of allelic imbalance with an increased expression of the IGF II gene in pre-cancerous lesions \[[@B36],[@B42]\].

The work has demonstrated that the allelic imbalance of the IGF II gene expression was seen in the early pre-cancerous lesions during hepatocarcinogenesis; but was not observed in well and moderately differentiated HCC.

Thus, some workers considered IGF II gene expression as an early event. Mixed reports are found which claimed the expression of IGFII either in preneoplasia \[[@B37],[@B38]\] or during HCC \[[@B34],[@B35]\]. The over expression of IGF II in HCC has been claimed to be associated with re-expression pattern of IGF II transcript occurring through activation of fetal promoters p2 -- p4 with a loss of activity of the adult promoter p1 \[[@B36]\]. Interestingly, the over expression of IGF II was found in the preneoplastic glycogen storage focal lesions maximally as compared to that in the basophilic lesions.

In mixed cell focal lesions as well as basophilic lesions, the expressions were low and in the mixed cell focal lesions the expression was particularly confined to the glycogen rich cells. When the expression was predominant almost throughout a lesion, this has been considered as an IGF II expressed lesion in this study. So, the trend of IGF II over expression in our study was in the sequence of \"high-low-high\" in \"glycogen storage foci -- mixed cell foci -- basophilic lesion -- HCC\". This suggests that the IGF II over expression is not only the early event, but the late event too. The gene expression amongst others appears to be responsible for cancer initiation process as well as in the progression of HCC. But its role during the progression from preneoplasia to neoplasia remains to be elucidated. Thus this gene over expression or may be the protein over expression can be used to detect the cancer at the early stage or at HCC and hence it may be considered as a future diagnostic means for detection of hepatic cancer and its stages and IGFII gene 33 expression could be considered as one of the best positive markers for early detection of putative preneoplastic cell as well as HCC in chemically induced hepatocarcinogenesis. Further investigation of this gene expression is warranted in the interest of better cancer detection. Thus this may lead to better cancer prevention. Again in contrast to many other gene or protein expressions IGFII has particular advantage for its use in screening of potential carcinogens and promoters since it is not expressed in lesions with some non-xenotoxic chemicals \[[@B39]\]. Further IGFII gene was reported to express at high levels in both spontaneous \[[@B40]\] and induced \[[@B41]\] hepatic lesions at the early stages of development \[[@B37],[@B38]\] and in HCC \[[@B32],[@B33]\].
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